The Sareum Holdings Plc (LON: SAR) share price edged 5.69% higher after announcing that its SDC-1801, lead TYK2/JAK1 kinase inhibitor, had been granted a patent in China. The company also revealed that its SDC-1802 drug candidate had also been granted a patent in the United States with several analogues.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
The clinical-stage biotech company noted that it could now explore other opportunities to use its SDC-1802 drug candidate as a therapy due to the analogues granted despite the drug’s primary focus being the immuno-oncology applications.
Top Broker Recommendation
- BlackBull 26,000+ Shares, Options, ETFs, Bonds, and other underlying assets – Read our Review
- Admiral Markets More than 4500 stocks & over 200 ETFs available to invest in – Read our Review
- Hargreaves Lansdown The company's website is easily understandable and accessible to a wide range of customers – Read our Review
- eToro Wide range of instruments available to trade – Read our Review
- IG Top-tier regulation – Read our Review
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY
SDC-1801 is a dual TYK2/JAK1 kinase inhibitor developed as a potential new therapeutic for various autoimmune diseases with an initial focus on psoriasis. Psoriasis is an autoimmune skin condition that affects over 60 million adults globally.
The market size for potential psoriasis treatments is estimated to be worth more than US$30 billion. Sareum recently revealed that it had started dosing healthy subjects in Phase 1a clinical trial for SDC-1801 in Australia.
The China National Intellectual Property Administration (CNIPA) has officially issued patent number CN113056456B, safeguarding SDC-1801 and its medical applications in treating inflammatory or immune disorders.
The patent issued for SDC-1801 is the first ever patent granted to Sareum in any global territory. The company noted that its patent applications in the US (US2021387981) and Europe (EP3864009) are still under review.
SDC-1802 is a TYK2/JAK1 inhibitor being developed for cancer immunotherapy. Sareum is still working on the translational studies needed to support the development of SDC-1802. The company wants to define the optimal cancer applications before completing the toxicology and manufacturing studies.
Dr John Reader, Sareum's Chief Scientific Officer, commented: “We’re delighted to have the first patent granted for SDC-1801, our lead development programme, which recently advanced into a Phase 1a clinical trial in Australia. We look forward to being able to strengthen our intellectual property around this asset in other territories in due course. Separately, we are really pleased to have extended the scope of patent protection for SDC-1802 in the US.”
The United States Patent and Trademark Office (USPTO) has formally granted patent number US 11,673,870 B2 for SDC-1802, explicitly covering the treatment of autoimmune disorders and several analogues.
*This is not investment advice.
Sareum share price.
The Sareum share price edged 5.69% higher to trade at 134.75p, from Friday’s closing price of 127.50p.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
